Navigation Links
SpectraScience Announces Results of Annual Shareholder Meeting
Date:9/22/2009

SAN DIEGO, Sept. 22 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, held its Annual Meeting of the Shareholders for the fiscal year ended 2008 at 9:00 am local time September 21, at the Del Mar Hilton in Del Mar, California. The business matters considered and acted upon at the meeting included (a) a vote to set the number of directors of the Company at six and election of six directors, and (b) amend the Company's Articles of Incorporation.

Only shareholders of record at the close of business on August 14, 2009 were entitled to vote at the meeting. Approximately 87% of the shares eligible to vote were cast in the above-mentioned matters. Approximately 99% of the shares were voted in favor of setting the number of directors of the Company at six and electing the six nominated directors, and approximately 96% were voted in favor of amending the Articles of Incorporation.

Also at the Annual Meeting, Jim Hitchin, President and Chief Executive Officer of SpectraScience, Inc., gave a presentation. Key highlights from the presentation included:

  • An overview of the business of SpectraScience, its technology and advantages including higher sensitivity in cancer screening, instantaneous detection of diseased tissue, the opportunity for treatment at the time of original patient visit and the ability to lower pathology costs, all leading to better overall patient care;
  • Highlights for the year including FDA approvals for WavSTAT(R) (colon cancer screening) and LUMA(R) (cervical cancer screening), EU approval for WavSTAT (colon & esophageal cancer screening), FDA clearance for manufacturing facility, the recently announced FDA clearance for a new WavSTAT platform, and the establishment of a European distribution network for WavSTAT; and
  • An update on the WavSTAT clinical trials (esophageal cancer screening) which are in process at Boston University, the Mayo Clinic, the Kansas City VA Hospital and the University of Southern California. The Company is also beginning esophageal clinical trials at multiple sites in the European Union.

Mr. Hitchin also discussed catalysts for the Company's growth moving forward, including: the growing and aging population; the increasing recognition of the value of testing as a way to improve health and reduce the overall costs of healthcare through early detection and prevention; the increasing access to tests that leverage advances in technology and cost efficiencies; the expanding role of diagnostics (early detection and intervention lead to better medical and economic outcomes); expansion of distribution and the addition of software applications to the technology platform to create leverage in the model for physicians and clinics.

Among those present at the meeting were members of the Company's board of directors, which includes Jim Hitchin, Stan Pappelbaum, M.D., Chet Sievert, F. Duwaine Townsen, and the Honorable Tommy Thompson. At the conclusion of the meeting, Gov. Thompson commented that, "It is a privilege to be associated with a company with as much promise as SpectraScience has in contributing to the fight against cancer. Jim Hitchin is doing a fantastic job developing this business and positioning the company to drive shareholder value."

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

    Contact:

    SpectraScience, Inc.
    Jim Hitchin, Chief Executive Officer
    (858) 847-0200 x201

    Hayden Communications
    Investor Relations
    Todd Pitcher
    (858)-518-1387


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. SpectraScience Receives Final European Certification
2. SpectraScience Acquires Luma Imaging Corporation
3. SpectraScience, Inc. Retains Hayden Communications
4. SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic
5. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Italy
6. SpectraScience Adds Industry Veteran to Executive Team
7. SpectraScience Awarded Patent for Correcting Image Misalignment
8. SpectraScience Delivers Cancer Diagnosis System to Mayo Clinic and UCSD/VA for Detecting Esophageal Dysplasia in Patients
9. SpectraScience Announces Updates
10. SpectraScience Awarded European Patent for Its Optical Biopsy System for Tissue Diagnosis
11. SpectraScience Awarded U.S. Patent 7,459,696 for its Unique Methods of Calibrating Spectral Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... , ... Amir Qureshi, MD is the first physician in Arkansas to implant ... The Nuvectra™ Algovita SCS System has been FDA approved as a treatment option for ... to introduce the most powerful SCS system and the only stretchable lead on the ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community health data ... are located in the Midwest. With the average cost of healthcare rising and the ... with both the quality and affordability of where they live. An annual 2017 report ...
(Date:5/26/2017)... ... May 26, 2017 , ... via seating is proud to ... task chair specifically designed for clinical areas. Genie Copper Mesh is a crossover ... Cupron® to provide customers with a game changing chair that is affordably priced,” ...
(Date:5/26/2017)... ... ... After raising nearly $30,000 on Kickstarter , about three-times its original campaign ... crowdfunding price on Indiegogo . , “Along with creating an anti-stress gadget to ... fidget toy to the market that was made of superior quality and wouldn’t break ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Silver Birch ... community, which is located on more than four acres of land at 5620 Sohl ... , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each of ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)... , May 5, 2017   Provista , a proven ... than 200,000 customers, today announced Jim Cunniff as ... of executive and business experience to Provista, including most recently ... in California . He assumed his new ... is a great fit for Provista," says Jody Hatcher ...
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
(Date:5/4/2017)... May 4, 2017  A new tight-tolerance microextrusion ... other highly-engineered materials, is being launched by Natvar, ... been developed in recent years to service a ... surgical applications. More expensive materials such as glass ... tubing due to their ability to consistently hold ...
Breaking Medicine Technology: